Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: Results from a randomized phase II study

Journal of Clinical Oncology

Volumn 26, Issue 14, 2008, Pages 2320-2326

  Kozuch, Peter S ^a   Rocha Lima, Caio Max ^a   Dragovich, Tomislav ^a   Hochster, Howard ^a   O'Neil, Bert H ^a   Atiq, Omar T ^a   Pipas, J Marc ^a   Ryan, David P ^a   Lenz, Heinz Josef ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; IRINOTECAN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CAMPTOTHECIN; DRUG DERIVATIVE; PYRAZINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; HUMAN; HYPOKALEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PATIENT ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; VOMITING; COLORECTAL TUMOR; CONTROLLED STUDY; DRUG ADMINISTRATION; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRAZINES; SURVIVAL RATE;

EID: 44249124775     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.0152     Document Type: Article

References (59)

1. American Cancer Society: Cancer Facts & Figures 2007. Atlanta, GA, American Cancer Society, 2007
2. Boyle P, Ferlay J: Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481-488, 2005
3. Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute: Stage distribution by race, sex and age group for colon and rectum cancer. SEER 9 Registries for 1988-2002. http://www.seer.cancer.gov
4. Goldberg RM: Advances in the treatment of metastatic colorectal cancer. Oncologist 10:40-48, 2005
5. Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1998
6. Rothenberg ML, Cox JV, DeVore RF, et al: A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85:786-795, 1999
7. Rougier P, Lepille D, Bennouna J, et al: Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: A randomised, multicentre phase II study. Ann Oncol 13:1558-1567, 2002
8. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
9. Vincenzi B, Santini D, Rabitti C, et al: Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: A single centre phase II trial. Br J Cancer 94:792-797, 2006
10. Giantonio BJ, Catalano PJ, Meropol NJ, et al: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 23:1s, 2005 (suppl; abstr 2)
11. Aghajanian C, Soignet S, Dizon DS, et al: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505-2511, 2002
12. Hamilton AL, Eder JP, Pavlick AC, et al: Proteasome inhibition with bortezomib (PS-341): A phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 23:6107-6116, 2005
13. Papandreou CN, Daliani DD, Nix D, et al: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108-2121, 2004
14. Dy GK, Thomas JP, Wilding G, et al: A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, Velcade), in patients with advanced cancer. Clin Cancer Res 11:3410-3416, 2005
15. Mackay H, Hedley D, Major P, et al: A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 11:5526-5533, 2005
16. Iqbal S, Kenz H-J, Groshen S, et al: Phase I study of PS-341 in combination with 5-FU/LV in solid tumors. Proc Am Soc Clin Oncol 21:93a, 2002 (abstr 370)
17. Cusack JC Jr, Liu R, Houston M, et al: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-κB inhibition. Cancer Res 61:3535-3540, 2001
18. Cusack JC Jr, Liu R, Baldwin AS Jr: Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappa B activation. Cancer Res 60:2323-2330, 2000
19. Ryan DP, Appleman LJ, Lynch T, et al: Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer 107:2482-2489, 2006
20. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
21. Sprangers MA, te Velde A, Aaronson NK, et al: The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). Eur J Cancer 35:238-247, 1999
22. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
23. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events, version 3.0. Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, March 31, 2003. http://ctep.cancer.gov
24. Pitot HC: US pivotal studies of irinotecan in colorectal carcinoma. Oncology 12:48-53, 1998
25. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
26. Simon R: Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 10:1-10, 1989
27. Dragovich T, Lenz HJ, Lima CMSR, et al: Bortezomib +/- irinotecan in relapsed/refractory colorectal cancer (CRC): Interim analysis results from phase (ph) 2b study. J Clin Oncol 22:267s, 2004 (suppl; abstr 3591)
28. Kamb A, Wee S, Lengauer C: Why is cancer drug discovery so difficult? Nat Rev Drug Disc 6:115-120, 2007
29. Scartozzi M, Bearzi I, Pierantoni C, et al: Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 25:3930-3935, 2007
30. Desai SD, Li T-K, Rodriguez-Bauman A, et al: Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 61:5926-5932, 2001
31. Kelland LR: "Of mice and men": Values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Canc 40:827-836, 2004
32. Johnson JI, Decker S, Zaharevitz D, et al: Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Canc 84:1424-1431, 2001
33. Voskoglou-Nomikos T, Pater JL, Seymour L: Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Canc Res 9:4227-4239, 2003
34. Kerbel RS: Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans. Canc Biol Ther 2:S134-S139, 2003
35. Cespedes MV, Casanova I, Parreno M, et al: Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol 8:318-329, 2006
36. Sausville EA, Burger AM: Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66:3351-3354, 2006
37. Man S, Munoz R, Kerbel RS: On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. Cancer Metastasis Rev 26:737-747, 2007
38. Jackson-Grusby L: Modeling cancer in mice. Oncogene 21:5504-5514, 2002
39. Van Dyke T, Jacks T: Cancer modeling in the modern era: Progress and challenges. Cell 108:135-144, 2002
40. Hood L, Perlmutter RM: The impact of systems approaches on biological problems in drug discovery. Nat Biotech 10:1215-1217, 2004
41. Butcher EC: Can cell systems biology rescue drug discovery? Nat Rev Drug Disc 4:461-467, 2005
42. Butcher EC, Berg EL, Kunkel EJ: Systems biology in drug discovery. Nat Biotech 22:1253-1259, 2004
43. Richardson PG, Sonneveld P, Schuster M, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
44. Pharmacia & Upjohn: Product Information: Camptosar®-irinotecan hydrochloride injection. July 2005
45. Popat R, Oakervee HE, Hallam S, et al: Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: Updated results after longer-term follow-up. Br J Haematol [epub ahead of print on March 27, 2008]
46. San Miguel JF, Richardson P, Sonneveld P, et al: Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX trial. Blood 106:111a, 2005 (abstr 366)
47. Richardson PG, Briemberg H, Jagannath S, et al: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113-3120, 2006
48. Siefker-Radtke AO, Poulter V, Matthew P, et al: Preliminary evidence of efficacy and tolerance for weekly intravenous bortezomib plus mitoxantrone in patients with advanced androgen-independent prostate cancer (AIPCa). J Clin Oncol 23:394s, 2005 (suppl; abstr 4567)
49. Dreicer R, Roth B, Petrylak D, et al: Bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer: A phase 1/2 study. Presented at ASCO Prostate Cancer Symposium, 2005 (abstr 250)
50. Morris MJ, Beekman KW, Kelley WK, et al: Phase II study of bortezomib for castrate metastatic prostate cancer (PC). J Clin Oncol 23:411s, 2005 (suppl; abstr 4633)
51. Aghajanian C, Dizon DS, Sabbatini P, et al: Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 23:5943-5989, 2005
52. Davies AM, McCoy J, Lara PN, et al: Bortezomib + gemcitabine (Gem)/carboplatin (Carbo) results in encouraging survival in advanced nonsmall cell lung cancer (NSCLC): Results of a phase II Southwest Oncology Group (SWOG) trial (S0339). J Clin Oncol 24:368s, 2006 (suppl; abstr 7017)
53. Lara PN, Koczywas M, Quinn DI, et al: Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: A phase I California Cancer Consortium trial. J Thorac Oncol 1:126-143, 2006
54. Markovic SN, Geyer SM, Dawkins F, et al: A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103:2584-2589, 2005
55. Dees EC, O'Neil BH, Humes EW, et al: A phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin. Breast Cancer Res Treat 82:S84, 2003 (suppl 1; abstr)
56. Davis NB, Taber DA, Ansari RH, et al: Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago Phase II Consortium study. J Clin Oncol 22:115-119, 2004
57. Kondagunta GV, Drucker B, Schwartz L, et al: Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 22:3720-3725, 2004
58. Caravita T, de Fabritiis P, Palumbo A, et al: Bortezomib: Efficacy comparisons in solid tumors and hematologic malignancies. Nature Clinical Practice Oncology 3:374-387, 2006
59. Rajkumar SV, Richardson PG, Hideshima T, et al: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630-639, 2005